Exchange
OTC
Every company in the roster listed on OTC.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
16 of 16 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 RocheRHHBY · OTC | 49 assets: 21 approved, 14 Ph 3, 9 Ph 2, 5 Ph 1 | astegolimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal | 8 Oct 2026RO7247669 · Phase 2 |
 UCBUCBJY · OTC | 16 assets: 9 approved, 1 Ph 3, 3 Ph 2, 3 Ph 1 | Staccato AlprazolamPhase 3 · EpilepsyReliable signal | 31 Oct 2026Staccato Alprazolam · Phase 3 |
 Merck KGaAMKKGY · OTC | 5 assets: 3 approved, 2 Ph 3 | NirogacestatPhase 3 · Multiple Myeloma | 28 May 2027Nirogacestat · Phase 2 |
 Bio-Path Holdings, Inc.BPTH · OTC | 3 assets: 1 Ph 2, 2 Ph 1 | BP1001Phase 2 · Acute Myeloid LeukemiaWeak signal | Mar 2027BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide · Phase 1 |
 BioAtla, Inc.BCAB · OTC | 3 assets: 3 Ph 2 | CAB-AXL-ADCPhase 2 · Non-Small Cell Lung CancerWeak signal | None on record |
 BioXcel Therapeutics, Inc.BTAI · OTC | 2 assets: 2 approved | Approved assets only | 31 Jul 2027Dexmedetomidine (Igalmi) · Phase 1 |
 CASI Pharmaceuticals, Inc.CASIF · OTC | 2 assets: 1 approved, 1 Ph 2 | CID-103Phase 1/2 · Immune ThrombocytopeniaWeak signal | May 2030CID-103 · Phase 1/2 |
| 2 assets: 1 Ph 2, 1 other | QR-333Phase 2 · Diabetic Peripheral Neuropathy | None on record | |
 Provectus PharmaceuticalsPVCT · OTC | 2 assets: 1 Ph 2, 1 other | PH-10Phase 2 · PsoriasisPartial signal | None on record |
 PureTech HealthPTCHF · OTC | 2 assets: 2 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 |
 Sangamo TherapeuticsSGMOQ · OTC | 2 assets: 2 other | isaralgagene civaparvovecFabry Disease | None on record |
 VaxxinityVAXX · OTC | 2 assets: 1 Ph 1, 1 other | UB-312Phase 1 · Parkinson's DiseasePartial signal | None on record |
 Windtree TherapeuticsWINT · OTC | 2 assets: 1 Ph 3, 1 other | IstaroximePhase 2/3 · Heart FailurePartial signal | None on record |
 CERo Therapeutics Holdings, Inc.CERO · OTC | 1 asset: 1 Ph 1 | CER-1236Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026CER-1236 · Phase 1 |
 NKGen BiotechNKGN · OTC | 1 asset: 1 Ph 2 | SNK01Phase 1/2 · Alzheimer's DiseaseWeak signal | Mar 2028SNK01 · Phase 1/2 |
 Vaccinex, Inc.VCNX · OTC | 1 asset: 1 Ph 2 | PepinemabPhase 1/2 · Alzheimer's DiseasePartial signal | 31 Dec 2028Pepinemab · Phase 1/2 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).